Sarepta Therapeutics, Inc. (SRPT) Forms Bullish Double Top; Strong Momentum for Buyers Coming

April 24, 2018 - By Nellie Frank

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Investors sentiment decreased to 1.22 in Q4 2017. Its down 1.66, from 2.88 in 2017Q3. It turned negative, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported.
Point72 Asset Mngmt Limited Partnership reported 0.14% stake. 295,322 were accumulated by Royal Bank & Trust Of Canada. Granite Point Capital Lp reported 0.24% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Jane Street Group Inc Llc, a New York-based fund reported 27,607 shares. Mutual Of America Cap Mgmt Limited Liability Corp invested in 0% or 1,200 shares. 22,732 are owned by Putnam Invests Lc. Hightower Advisors Lc accumulated 0.03% or 68,518 shares. Lucas Mgmt accumulated 5,500 shares. Principal Financial Gp invested 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Cubist Systematic Strategies accumulated 973 shares. Cornerstone Mngmt Hldgs Limited Liability Corp owns 24,294 shares or 0.01% of their US portfolio. California Employees Retirement Systems reported 146,700 shares stake. 23,200 were reported by Gam Holdings Ag. New Jersey-based Bessemer Grp Incorporated has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Atika Management Limited Liability Company stated it has 1.98% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

The chart of Sarepta Therapeutics, Inc. (SRPT) shows a double top with $82.96 target or 9.00 % above today’s $76.11 share price. The 5 months chart pattern indicates low risk for the $4.95 billion company. It was reported on Apr, 24 by If the $82.96 price target is reached, the company will be worth $445.05M more. Double tops are rare but powerful chart patterns.

The stock decreased 2.82% or $2.2 during the last trading session, reaching $76.11. About 424,098 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 24, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on April, 26. They expect $-0.32 EPS, up 56.16 % or $0.41 from last year’s $-0.73 per share. After $-0.37 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -13.51 % EPS growth.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 14 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Sarepta Therapeutics has $100 highest and $49 lowest target. $80.08’s average target is 5.22% above currents $76.11 stock price. Sarepta Therapeutics had 24 analyst reports since October 26, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, March 12 by Piper Jaffray. The company was maintained on Thursday, March 15 by SunTrust. RBC Capital Markets initiated the shares of SRPT in report on Monday, January 22 with “Buy” rating. JP Morgan maintained the stock with “Overweight” rating in Wednesday, February 21 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, March 21. The firm has “Buy” rating by Needham given on Thursday, October 26. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Overweight” rating given on Tuesday, March 6 by Morgan Stanley. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Monday, March 12 by H.C. Wainwright. As per Tuesday, March 13, the company rating was maintained by Credit Suisse. Leerink Swann maintained it with “Outperform” rating and $92 target in Tuesday, March 13 report.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: